Supernus Pharmaceuticals (SUPN) Q3 FY26 earnings call

Supernus demonstrated accelerating commercial traction across core growth drivers ahead of its pending transformative merger with Indivior Pharmaceuticals. Expansion across adult ADHD and postpartum depression franchises drove improved profitability, while supply chain and integration milestones de-risk execution into the pending transaction closing.